Status:
RECRUITING
Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
Bayer
Conditions:
Chronic Thromboembolic Disease (CTED)
Exercise Intolerance Post PEA Surgery
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).
Eligibility Criteria
Inclusion
- Adult patients who underwent PTE or BPA for Chronic thromboembolic pulmonary hypertension (CTEPH) at least six months prior to screening and report ongoing subjective exercise limitation,
- able to give consent
- able to perform a exercise protocol
Exclusion
- Patients with known Residual Pulmonary Hypertension (RPH) by RHC following PTE for CTEPH
- ongoing PAH-specific vasodilator therapy
- known contraindication to riociguat
- a physical limitation to completing an exercise protocol
Key Trial Info
Start Date :
June 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03409588
Start Date
June 13 2018
End Date
December 1 2024
Last Update
May 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado, Anschutz Medical Campus
Aurora, Colorado, United States, 80045